World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat

Suzuki, Hidekazu; Mori, Hideki

doi:10.1007/s00535-017-1407-1

Cited by 118 publications

(101 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Helicobacter pylori ( H. pylori ) infection causes a number of diseases, including chronic atrophic gastritis, peptic ulcer, gastric cancer, and gastric mucosa‐associated lymphoid tissue (MALT) lymphoma . Nearly half of the world's population is reported to be infected with H. pylori .…”

Section: Introductionmentioning

confidence: 99%

Systematic review with meta‐analysis: Vonoprazan, a potent acid blocker, is superior to proton‐pump inhibitors for eradication of clarithromycin‐resistant strains of Helicobacter pylori

et al. 2018

View full text Add to dashboard Cite

Vonoprazan-based and conventional PPI-based therapies are similarly effective for the eradication of clarithromycin-susceptible H. pylori strains. Vonoprazan is superior to conventional PPI-based therapy for the eradication of clarithromycin-resistant H. pylori strains. However, clarithromycin was misused because the combination of vonoprazan and amoxicillin cures approximately 80% of infections without clarithromycin.

show abstract

Section: Introductionmentioning

confidence: 99%

Systematic review with meta‐analysis: Vonoprazan, a potent acid blocker, is superior to proton‐pump inhibitors for eradication of clarithromycin‐resistant strains of Helicobacter pylori

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In a recent study, the incidence of GC is generally in direct proportion to the prevalence of H pylori infection. And higher incidences of gastric cancer are found in countries in eastern Asia than in other countries . Although early GC has a 5‐year survival rate of 90% or more with complete resection, advanced GC is known to have poor prognosis even if resection is possible .…”

Section: Introductionmentioning

confidence: 99%

The prevalence of histologic atrophy and intestinal metaplasia in the corpus has decreased over 15 years in females in the Korean population

et al. 2019

View full text Add to dashboard Cite

Background The aim of this study was to investigate the trends of atrophy and intestinal metaplasia (IM) in 2002 subjects without significant gastroduodenal diseases. Materials and Methods A total of 2002 subjects were prospectively enrolled and divided into three periods (2003‐2007, 2008‐2012, and 2013‐2018). Trends of H pylori and atrophy/IM scored by Updated Sydney System were analyzed according to sex, and multivariate logistic analysis was performed for the risk factors for atrophy/IM. Results H pylori‐negative and H pylori‐positive subjects were 1220 (61.0%) and 782 (38.0%), respectively. H pylori positivity decreased from 149/303 (49.2%), 207/515 (40.2%) and 426/1184 (36.0%), in the three periods, respectively (P < 0.001). The prevalence of atrophy (P < 0.001) and IM in the corpus (P < 0.001) significantly decreased over 15 years in females, but not in males. The mean grade of atrophy and IM was higher in males (0.36 and 0.51) than in females (0.28 and 0.41) in the corpus (P = 0.027) and in the antrum (P = 0.006), respectively. Similarly, the mean grade of IM in males (0.34) was higher in females (0.19; P < 0.001) in the corpus. Multivariate analysis showed that old age, study period, and H pylori were statistically significant in atrophy of antrum and corpus, and IM in the corpus. In cases of IM of antrum, old age, H pylori, and smoking were statistically significant. Conclusion A significant decrease in atrophy and IM in the corpus in females over 15 years suggests sex‐ or gender‐specific characteristics.

show abstract

“…11 The association of changes in the gut microbiota with the development of constipation is well known. 11 The association of changes in the gut microbiota with the development of constipation is well known.…”

Section: Introductionmentioning

confidence: 99%

Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation

et al. 2018

View full text Add to dashboard Cite

Backgrounds and Aims Constipation is one of the most common gastrointestinal functional disorders. Recently, the gut microbiota has been implicated in the development of constipation. Helicobacter pylori infection is considered to be a possible factor influencing the gut microbiota profile. Here, we investigated the effect of H. pylori eradication therapy on symptoms of chronic constipation. Methods We recruited 166 H pylori‐positive patients who underwent eradication therapy after endoscopy. We evaluated the severity of symptoms of chronic constipation before eradication therapy and 2 months post‐therapy using two questionnaires, the Gastrointestinal Symptom Rating Scale (GSRS) and the Izumo scale. In addition, we evaluated association with constipation and H. pylori infection in patients with constipation‐related symptoms in not only all patients, but also patients with the constipation‐related symptoms in relation to eradication outcome, the severity of constipation‐related symptoms, and the severity of endoscopic gastric mucosal atrophy. Results Mean GSRS scores were 5.10 ± 2.67 in all patients and 6.15 ± 2.91 in constipation patients which were significantly lower than that before eradication (5.78 ± 3.27, P < 0.01 and 8.19 ± 3.09, P < 0.01, respectively). Constipation‐related scores of the GSRS questionnaire in the successful eradication group were significantly improved after eradication from 5.63 ± 3.06 in all patients and 8.00 ± 2.85 in constipation patients to 5.11 ± 2.71 (P = 0.02) and 6.16 ± 2.96 (P < 0.01), while scores in the failed eradication group before and after eradication were similar. Constipation‐related scores in patients with mild gastric atrophy (Kimura‐Takemoto classification, C‐I to O‐I) were significantly decreased after eradication, but were not decreased in patients with severe atrophy (O‐II and O‐III). Conclusions Successful eradication therapy for H. pylori infection may confer additional benefits in H. pylori‐positive patients with symptoms of chronic constipation, especially in patients with mild gastric atrophy.

show abstract

World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat

Cited by 118 publications

References 69 publications

Systematic review with meta‐analysis: Vonoprazan, a potent acid blocker, is superior to proton‐pump inhibitors for eradication of clarithromycin‐resistant strains of Helicobacter pylori

Systematic review with meta‐analysis: Vonoprazan, a potent acid blocker, is superior to proton‐pump inhibitors for eradication of clarithromycin‐resistant strains of Helicobacter pylori

The prevalence of histologic atrophy and intestinal metaplasia in the corpus has decreased over 15 years in females in the Korean population

Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation

Contact Info

Product

Resources

About